Inflammatory Bowel Disease Treatment Market Report 2024: Market Outlook

The inflammatory bowel disease treatment market size has grown strongly in recent years. It will grow from $23.49 billion in 2023 to $25.56 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increased prevalence of inflammatory bowel disease, growing demand for biologics and immunomodulators, advancements in treatment options, rising geriatric population, increased awareness about the disease.

The inflammatory bowel disease treatment market size is expected to see strong growth in the next few years. It will grow to $36.63 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing investment in research and development activities, growing demand for biosimilars, rising incidence of inflammatory bowel disease in emerging markets, growing demand for personalized medicine, integration of precision medicine in ibd treatment. Major trends in the forecast period include increasing number of product launches and approvals, personalized dosing and treatment plans in ibd management, use of telemedicine for remote monitoring of ibd patients, exploration of microbiome-based therapies for ibd, adoption of value-based care models in ibd treatmen.

Market Overview -
Inflammatory bowel disease treatment refers to anti-inflammatory medications that are commonly used to treat mild to moderate ulcerative colitis. Aminosalicylates such as mesalamine (Delzicol, Rowasa, and other brands), balsalazide (Colazal), and olsalazine are anti-inflammatories (Dipentum).

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

The Surge In Inflammatory Bowel Diseases Spurs Growth In Treatment Market
The rising prevalence of Crohn's disease and ulcerative colitis is significantly driving the inflammatory bowel disease treatment market. Crohn's disease and ulcerative colitis are types of inflammatory bowel diseases (IBD) that cause inflammation and ulcers (sores) in the digestive tracts. The rising cases of Crohn's disease and ulcerative colitis are expected to boost demand for inflammatory bowel disease treatments, as they are widely used to reduce bowel inflammation and reduce and prevent medical complications. For instance, according to March 2022 research published in the United States National Library of Medicine, a US-based medical library, around 1.6 million Americans currently suffer from inflammatory bowel disease (Crohn's disease or ulcerative colitis) and around 70,000 new cases of IBD are diagnosed every year in the USA. Hence, the rising prevalence of Crohn's disease and ulcerative colitis is expected to drive the inflammatory bowel disease treatment market growth.

Competitive Landscape -
Major companies operating in the inflammatory bowel disease treatment market report are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Union Chimique Belge S. A., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic - Gastroenterology West P. C., Ebony 60 Inc., Salix Pharmaceuticals Inc., Shire plc, Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.

Embracing Technological Advancements In Inflammatory Bowel Disease Treatment
Technological advancement is a key trend gaining popularity in the inflammatory bowel disease treatment market. The key players in the inflammatory bowel disease treatment market are focusing on using technology such as artificial intelligence (AI) for the drug discovery process as well as offering advanced but new inflammatory bowel disease treatments. To attain their technological innovations, key players and technology companies are partnering to leverage each other's competencies and technology to develop new treatments and strengthen their key position in the market. For instance, in May 2021, CytoReason, an Israeli technology start-up developing a computational model of the human body, partnered with Ferring Pharmaceuticals, a Switzerland-based multinational pharmaceutical company to develop new inflammatory bowel disease treatments (IBD) using artificial intelligence technology during the drug discovery process. Ferring's medical expertise will be combined with CytoReason's artificial intelligence (AI) technology to create cell-centred illness models. The AI technology enables scientists to gain critical information on the body's functioning and treats diseases at the cellular level.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Key Segments -
The inflammatory bowel disease treatment market covered in this report is segmented -

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn's Disease, Ulcerative Colitis
3) By Route of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.